Workers in protective clothing and masks operate a bottling and packaging line at a pharmaceutical production facility in Samarra.
Samarra state pharmaceutical company launches August production plan worth over 3.4 billion dinars
SAMARRA — The State Company for Drugs and Medical Appliances in Samarra announced Thursday the launch of its August production program, valued at more than 3.4 billion dinars ($2.43 million), aimed at strengthening pharmaceutical security and reducing imports.
“The production program for August exceeded 3.477 billion Iraqi dinars,” said company director general Mohammed Abdulqader Al-Nuaimi. “It includes the manufacture of a wide range of new and standard pharmaceutical products in various forms such as tablets, capsules, syrups, ointments, and others to meet the needs of the local market and hospitals.”
Al-Nuaimi said production is carried out under marketing contracts signed with the Ministry of Health and a specialized marketing agency to ensure delivery of medicines to all Iraqi governorates “at reasonable prices and in compliance with international quality standards.”
He added that the program is part of the company’s strategy “to achieve self-sufficiency in essential medicines, reduce shortages in the market, and support government health institutions in a way that contributes to strengthening the national health sector.”
In August 2025, the State Company for Drugs and Medical Appliances in Samarra told 964media it had prepared over 21 new medicines for chronic and general illnesses and plans to launch seven more within two months, including treatments for diabetes, hypertension, acne, arthritis, and pain relief.